Hone Health, a physician-led virtual longevity care platform, has raised $228 million.
The investment is structured as a combination of equity and growth financing. The $28 million series A extension was led by MarcyPen Capital Partners, with participation from Pentland Ventures, Kinship Ventures, Hanwha, Gannet Capital, humbition and Comma Capital. Other angel investors also participated, including the Jonas brothers. The $200 million in growth financing came from General Catalyst’s Customer Value Fund.
Hone will use the investment to support a number of expansions. It plans to launch more programming for metabolic health, PMOS, inflammation and immunity, and to launch a physician-supervised peptide program. It will add more diagnostics, including coronary CT angiography and gut microbiome analysis.
Hone also plans to continue building out its AI operating system that brings data together to help personalize care. And, it plans to build out clinical trial infrastructure to support pharma partners.
“Longevity is thought of as this super exotic thing. … I actually think longevity is now becoming primary care,” Saad Alam, co-founder and CEO of Hone, told Fierce Healthcare.
It costs $65 to test for 70 biomarkers with Hone, followed by a clinician consult with the option to add more diagnostics. Labs, health history, symptoms and medications are run through its AI, which then gives providers treatment recommendations. Hone can keep adding additional diagnostics and medications, per Alam, “and the AI gets smarter as we get more patients into that system.”
From there, patients can become subscribers. A subscription is $150 a month, plus the cost of medications. Medications can be covered by a patient’s health plan, though Alam noted most still choose to pay for meds out-of-pocket. Hone does not mark up its prescriptions, he said. Two-thirds of Hone patients have an annual family income of between $50,000 to $100,000.
Additionally, Hone is publicly announcing Hone Black, a new concierge longevity membership that has operated in stealth for a select group of patients for the past year. It combines diagnostics on over 1,600 health markers with ongoing medical care from physicians. Offerings include prescriptions, supplements, peptides and lifestyle guidance, plus exosome and stem cell therapies.
Alam founded the company after experiencing a shift in his health at 35 years old, including mental health issues, depression and weight gain. His doctor was initially of little help. It took Alam a year to find out he had low testosterone, and after treatment, he finally felt back on track. That experience, along with his father dying from kidney disease and his mother going through early menopause, opened his eyes to the longevity space.
“This whole concept of longevity is going to be one of the single greatest problems I can dedicate my life to solving,” Alam realized at the time. He experimented with everything, from peptides to cold plunges to meditation.
Hone is a subsidiary of Time Therapeutics, which aims to support production of drugs that help people live longer. Alam, who started his career doing market research at Eli Lilly, knew clinical trials are expensive and inaccessible. He wanted to create a company that can help commercialize drugs. The first step to that is Hone, or a DTC virtual care company that can capture longitudinal data on patients. The next phase will be publishing research. Finally, Hone will look to partner with pharma to get drugs to market faster.
The company has been providing care for five years, treating about 200,000 patients to date. It requires patients to have a physician and get bloodwork every 90 days in order to get medication refills. Members can contact their clinician between sessions as needed.
“We make sure for the most part that you are doing bloodwork and talking to a physician, a real conversation with a physician, in order to get prescribed medication,” Alam said.
It isn’t about overprescribing medications. It’s about finding the most personalized protocol for each patient. “The companies that have—no pun intended—longevity, are the ones that are going to figure out how to reduce the number of medications somebody might need,” Alam said.
Hone began with hormone therapy, since then moving into longevity care with biomarkers analysis and women’s health. Two months ago, Hone’s offerings for women surpassed offerings for men in terms of net new members. It soon plans to run clinical trials on poly-chronic patients as well to help determine the right drug at the right time. Hone crossed $100 million in revenue in 2025, per Alam, and is on track to double this year.
“When I started goop, wellness was a niche conversation,” Gwyneth Paltrow, founder and CEO of goop and co-founder of Kinship Ventures, said in a press release. “Today it’s one of the biggest categories in the world, and the next step is bringing real health and wellness to the masses, not just the few. Saad has built Hone to do exactly that, with serious science and at real scale. That’s why Kinship invested, and we could not be more excited about what’s ahead.”
Hone will soon offer 14 longevity care categories, which Alam argues is akin to primary care. He estimates Hone only refers to in-person care about 10% of the time, usually for higher acuity conditions. Some Hone patients are already healthy; most are sick and willing to pay out of pocket, because the current system has been inadequate in solving their health needs, per Alam.
“This is just the beginning of not only a way but a complete change in the way that medicine is practiced,” Alam said. “A lot of other companies are what I’ll call pill mills, and where we’ve really focused our energy is making sure that we go through the more difficult work of managing the long-term health of our patients.”